What ridiculousness is everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY), spewing on the last day of 2020? How about some hype around a journal article highlighting a case series of four Covid-19 patients (two of whom died) treated with loserlimab in the impressive sounding “Journal of Translational Autoimmunity.”
First some obvious caveats, this case series appears to be cherry picking rehash of the previous EIND patients, as all patients were admitted in April or May of 2020. There is no control group. Two of the four patients died, and one of the two surviving patients refused the second dose of loserlimab.
But more importantly, the Journal of Translational Autoimmunity is what is politely known as an “Open Access” journal. More colloquially, this is known as a “Pay for Play” journal. Yes, that is right, authors pay to be “published.” How much will an article in this prestigious journal cost you? A stock promoting bargain at $2250.00 not including sales tax.
Look it up for yourselves.
One thing that Cytodyn did not press release today and likely does not want you to know about is this:
This means the shares, owned by John M. Fife, that were registered to be sold on the S-3/A the other day are now free to hit the market.
Happy New Year!
[Did you know Cytodyn is being sued by a group of former directors? What to know why? See here and here.]
[Did you know Loserlimab has virtually no chance of ever getting an EUA in the United States? Want to know why? See here.]
* Spelled Thusly For A Double Dose of That Sweet Sweet Stock Pimping